Form 4: EyePoint Pharmaceuticals Executive Vice Chair Reports Stock Transactions
SEC Form 4 Filing
Nancy Lurker, Executive Vice Chair of EyePoint Pharmaceuticals, reports the vesting of restricted stock units and subsequent disposal of shares to cover taxes.
Summary
- On July 10, 2024, Nancy Lurker, the Executive Vice Chair of EyePoint Pharmaceuticals, had 11,111 shares of common stock vest from restricted stock units.
- These shares were acquired at a price of $0.00.
- Following the transaction, Lurker directly owns 94,462 shares of common stock.
- Lurker also indirectly owns 126,889 shares through a family trust.
- The restricted stock units vest in three ratable annual installments beginning July 10, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 07/10/2024 | Date of transaction: vesting of restricted stock units and disposal of shares. |
| 07/10/2024 | First vesting date of restricted stock units. |
| 07/12/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.